摘要：Follicular lymphoma (FL) is an indolent non-Hodgkin’s lymphoma that remains an incurabledisease for most patients. It is responsive to a variety of different treatments, howeverit follows a pattern of relapsing and remitting disease. Traditional therapeutic options forpatients with untreated FL include a “watchful waiting” approach for asymptomatic andlow tumor burden and multiagent cytotoxic chemotherapy for symptomatic and/or hightumor burden. The life expectancy of patients with FL has been extended with the useof rituximab, but there remains a group of patients who fail to respond to chemoimmunotherapy.So there is a need for useful novel prognostic factors and scoring systems forprediction of the disease course of single patients to individualize therapy, especially inthe new era of chemoimmunotherapy. The identification of novel targeted agents, useof stem cell transplantation, and new treatment combinations provide the opportunity toenhance patient outcomes
